These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36153530)

  • 1. Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial.
    Endo A; Yamakawa K; Tagami T; Umemura Y; Takahashi K; Nagasawa H; Araki Y; Kojima M; Sera T; Yagi M; Yamamoto R; Takahashi J; Nakane M; Takeda C; Narita C; Kazuma S; Okura H; Takahashi H; Wada T; Tahara S; Matsuoka A; Masaki T; Shiraishi A; Shimoyama K; Yokokawa Y; Nakamura R; Sageshima H; Yanagida Y; Takahashi K; Otomo Y
    Trials; 2022 Sep; 23(1):799. PubMed ID: 36153530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin versus norepinephrine infusion in patients with septic shock.
    Russell JA; Walley KR; Singer J; Gordon AC; Hébert PC; Cooper DJ; Holmes CL; Mehta S; Granton JT; Storms MM; Cook DJ; Presneill JJ; Ayers D;
    N Engl J Med; 2008 Feb; 358(9):877-87. PubMed ID: 18305265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selepressin, a novel selective vasopressin V
    Russell JA; Vincent JL; Kjølbye AL; Olsson H; Blemings A; Spapen H; Carl P; Laterre PF; Grundemar L
    Crit Care; 2017 Aug; 21(1):213. PubMed ID: 28807037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic Instability Secondary to Vasopressin Withdrawal in Septic Shock.
    Bissell BD; Magee C; Moran P; Bastin MLT; Flannery AH
    J Intensive Care Med; 2019 Sep; 34(9):761-765. PubMed ID: 28750598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock-a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial.
    David S; Bode C; Stahl K;
    Trials; 2023 Apr; 24(1):277. PubMed ID: 37061693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial.
    Legrand M; Oufella HA; De Backer D; Duranteau J; Leone M; Levy B; Rossignol P; Vicaut E; Dépret F;
    Trials; 2020 Jul; 21(1):601. PubMed ID: 32611377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
    Dellinger RP; Levy MM; Carlet JM; Bion J; Parker MM; Jaeschke R; Reinhart K; Angus DC; Brun-Buisson C; Beale R; Calandra T; Dhainaut JF; Gerlach H; Harvey M; Marini JJ; Marshall J; Ranieri M; Ramsay G; Sevransky J; Thompson BT; Townsend S; Vender JS; Zimmerman JL; Vincent JL; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Crit Care Med; 2008 Jan; 36(1):296-327. PubMed ID: 18158437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.
    Unger M; Morelli A; Singer M; Radermacher P; Rehberg S; Trimmel H; Joannidis M; Heinz G; Cerny V; Dostál P; Siebers C; Guarracino F; Pratesi F; Biancofiore G; Girardis M; Kadlecova P; Bouvet O; Zörer M; Grohmann-Izay B; Krejcy K; Klade C; Krumpl G
    Trials; 2018 Nov; 19(1):637. PubMed ID: 30454042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial to determine whether septic shock-reversal is quicker in pediatric patients randomized to an early goal-directed fluid-sparing strategy versus usual care (SQUEEZE): study protocol for a pilot randomized controlled trial.
    Parker MJ; Thabane L; Fox-Robichaud A; Liaw P; Choong K;
    Trials; 2016 Nov; 17(1):556. PubMed ID: 27876084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
    Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
    Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.
    Morelli A; Ertmer C; Rehberg S; Lange M; Orecchioni A; Cecchini V; Bachetoni A; D'Alessandro M; Van Aken H; Pietropaoli P; Westphal M
    Crit Care; 2009; 13(4):R130. PubMed ID: 19664253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock.
    Anantasit N; Boyd JH; Walley KR; Russell JA
    Crit Care Med; 2014 Aug; 42(8):1812-20. PubMed ID: 24919159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted tissue perfusion versus macrocirculation-guided standard care in patients with septic shock (TARTARE-2S): study protocol and statistical analysis plan for a randomized controlled trial.
    Pettilä V; Merz T; Wilkman E; Perner A; Karlsson S; Lange T; Hästbacka J; Hjortrup PB; Kuitunen A; Jakob SM; Takala J
    Trials; 2016 Aug; 17():384. PubMed ID: 27484695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of initial monotherapy with norepinephrine versus vasopressin for resuscitation in septic shock.
    Daley MJ; Lat I; Mieure KD; Jennings HR; Hall JB; Kress JP
    Ann Pharmacother; 2013 Mar; 47(3):301-10. PubMed ID: 23447481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of continuous vasopressin infusion in patients with septic shock.
    Obritsch MD; Jung R; Fish DN; MacLaren R
    Ann Pharmacother; 2004; 38(7-8):1117-22. PubMed ID: 15178740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Open-label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock.
    Hammond DA; Ficek OA; Painter JT; McCain K; Cullen J; Brotherton AL; Kakkera K; Chopra D; Meena N
    Pharmacotherapy; 2018 May; 38(5):531-538. PubMed ID: 29600824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central venous pressure value can assist in adjusting norepinephrine dosage after the initial resuscitation of septic shock.
    Li DK; Du W
    Chin Med J (Engl); 2019 May; 132(10):1159-1165. PubMed ID: 30946069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock.
    Hammond DA; Cullen J; Painter JT; McCain K; Clem OA; Brotherton AL; Chopra D; Meena N
    J Intensive Care Med; 2019; 34(11-12):910-916. PubMed ID: 28820036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.
    Roggeveen LF; Fleuren LM; Guo T; Thoral P; de Grooth HJ; Swart EL; Klausch TLT; van der Voort PHJ; Girbes ARJ; Bosman RJ; Elbers PWG
    Trials; 2019 Dec; 20(1):745. PubMed ID: 31852491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.